ClinicalTrials.gg
CompletedNCT00969592Updated Sep 2, 2009

Expanded PK and PD of Insulin Glulisine Versus Insulin Aspart in Healthy Volunteers

A Phase 1 interventional study of insulin glulisine, insulin aspart and insulin aspart, insulin glulisine in Diabetes, sponsored by Profil Institut für Stoffwechselforschung GmbH. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-09-02.

Sponsored by Profil Institut für Stoffwechselforschung GmbH · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing insulin glulisine in Diabetes Mellitus — none open to participants now, none under way, none of them phase 3. insulin glulisine · Diabetes Mellitus.

Enrollment
16th of 16
12 · median 169
Started
2007
with 5 others
Phase 1
3 of 17
none open now
Registered
13th of 17
by date
Lead sponsor
1 of 17
Profil Institut für Stoffwechselforschung GmbH

Among the 17 studies testing insulin glulisine in Diabetes Mellitus, this one is the 16th largest by enrollment of the 16 interventional ones that give a count, is one of 6 that started in 2007, is one of 3 in phase 1, and was the 13th registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

None of the 17 studies testing insulin glulisine in Diabetes Mellitus is open now. The open studies under Diabetes Mellitus, anywhere →

About insulin glulisine

insulin glulisine: first FDA approval 2004 (APIDRA SOLOSTAR), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 17 studies testing insulin glulisine in Diabetes Mellitus as a file.
02

Study summary

The purpose of this study was to compare the pharmacodynamics (course of the blood glucose-lowering effect and duration of effect) and pharmacokinetics (course of the concentration of study medication in the blood) of a single subcutaneous dose of 0.2 units/kg of insulin glulisine and insulin aspart in a direct head-to-head comparison during two euglycemic glucose clamps in healthy subjects.

Read the detailed description

In a previous glucose clamp study with a head-to-head comparison of insulin glulisine and insulin lispro it was shown that the onset of metabolic action was significantly shorter with insulin glulisine than with insulin lispro (while the total metabolic effect was not different). These results were in line with a faster early insulin exposure of insulin glulisine compared to insulin lispro. The primary aim of this study was to investigate whether or not these favorable characteristics of insulin glulisine were also evident in the comparison against insulin aspart. This was the first clinical study realizing a head-to-head comparison between these two insulin analogs.

03

Conditions studied

  • Diabetes

Browse trials for

Keywords

  • diabetes
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Overtly healthy males or females (Women: , Pearl Index \<1%)
  • Between the ages of 18 and 65 years
  • of \<= 27 kg/m²
  • Safety lab within reference range
  • Normal blood pressure and heart rate
  • Sufficient venous access
  • Written approved by the Ethical Review Board
  • and fasting plasma glucose in the normal range

Exclusion criteria

Exclusion Criteria:

  • Investigative site personnel directly affiliated with this study and their immediate families or the sponsor´s employees
  • Within 30 days of the initial dose of study drug had received treatment with a drug that had not received regulatory approval
  • Known allergies to insulin or related compounds
  • Regular treatment with any drug, both over-the-counter or prescribed
  • an abnormality in the 12-lead increasing the risk for participation
  • History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs
  • Significant active neuropsychiatric disease
  • Regular use of drugs of abuse and or positive findings on urinary drug screening
  • Evidence of and/or positive antibodies 1 or 2 and or HIV1 antigen
  • Evidence of and/or positive antibody
  • Evidence of hepatitis B and/or positive hepatitis B surface antigen
  • Women with a positive pregnancy test or breastfeeding women
  • Blood donation more than 500 mL within the last 3 months
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
12 participants (actual)

Study arms

  • Active comparator
    insulin glulisine, insulin aspart

    insulin glulisine administration during first glucose clamp, insulin aspart administration during second glucose clamp

    Drug: insulin glulisine, insulin aspart

  • Active comparator
    insulin aspart, insulin glulisine

    insulin aspart administration during first euglycemic clamp, insulin glulisine administration during second clamp

    Drug: insulin aspart, insulin glulisine

Interventions

  • Druginsulin glulisine, insulin aspart

    Drug pages: Insulin glulisine · Insulin Aspart

    single subcutaneous dose of 0.2 units per kg body weight of insulin glulisine during first euglycemic glucose clamp, single subcutaneous dose of 0.2 units per kg body weight of insulin aspart during second euglycemic glucose clamp

    Also known as: Apidra, NovoRapid

  • Druginsulin aspart, insulin glulisine

    Drug pages: Insulin Aspart · Insulin glulisine

    single subcutaneous dose of 0.2 units per kg body weight of insulin aspart during first euglycemic glucose clamp, single subcutaneous dose of 0.2 units per kg body weight of insulin glulisine during second euglycemic glucose clamp

    Also known as: NovoRapid, Apidra

06

What researchers measure

Primary outcomes

  1. fractional and total glucose infusion rates

    Time frame: 0-1 hours, 0-2 hours, and time to 10% of GIRmax

Secondary outcomes

  1. fractional and total insulin areas under the curve (AUC)

    Time frame: 0-1 hours, 0-2 hours, 0-10 hours

07

Study locations

1 site
  • Profil Institut für Stoffwechselforschung GmbH
    Neuss, D-41460, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Dec 2007 and a completion of Jun 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2009
First posted
Sep 1, 2009
Start
Nov 2007
Primary completionActual
Dec 2007
CompletionActual
Jun 2008
Last update
Sep 2, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00969592
Collaborators
Sanofi
First posted
Sep 1, 2009
Start date
Nov 2007
Primary completion
Dec 2007
Completion
Jun 2008
Last update
Sep 2, 2009

Study contacts

Sabine Arnolds, MD
principal investigator · Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin glulisine · Insulin Aspart

Start the discussion